These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29603877)

  • 1. Concordance of somatic mutational profile in multiple primary melanomas.
    Adler NR; McLean CA; Wolfe R; Kelly JW; McArthur GA; Haydon A; Tra T; Cummings N; Mar VJ
    Pigment Cell Melanoma Res; 2018 Sep; 31(5):592-603. PubMed ID: 29603877
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concordance of somatic mutation profiles (BRAF,NRAS, and TERT) and tumoral PD-L1 in matched primary cutaneous and metastatic melanoma samples.
    Yang S; Leone DA; Biswas A; Deng A; Jukic D; Singh R; Sundram U; Mahalingam M
    Hum Pathol; 2018 Dec; 82():206-214. PubMed ID: 30120967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis.
    Pellegrini C; Di Nardo L; Cipolloni G; Martorelli C; De Padova M; Antonini A; Maturo MG; Del Regno L; Strafella S; Micantonio T; Leocata P; Peris K; Fargnoli MC
    J Mol Diagn; 2018 Jan; 20(1):110-122. PubMed ID: 29061376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.
    Adler NR; Wolfe R; Kelly JW; Haydon A; McArthur GA; McLean CA; Mar VJ
    Br J Cancer; 2017 Sep; 117(7):1026-1035. PubMed ID: 28787433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Carlino MS; Haydu LE; Kakavand H; Menzies AM; Hamilton AL; Yu B; Ng CC; Cooper WA; Thompson JF; Kefford RF; O'Toole SA; Scolyer RA; Long GV
    Br J Cancer; 2014 Jul; 111(2):292-9. PubMed ID: 24918823
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.
    Adler NR; Wolfe R; McArthur GA; Kelly JW; Haydon A; McLean CA; Mar VJ
    Br J Cancer; 2018 May; 118(10):1289-1295. PubMed ID: 29755118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases.
    Pellegrini C; Cardelli L; Padova M; Nardo LD; Ciciarelli V; Rocco T; Cipolloni G; Clementi M; Cortellini A; Ventura A; Leocata P; Fargnoli MC
    Acta Derm Venereol; 2020 Jan; 100(1):adv00040. PubMed ID: 31774543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT, BRAF, and NRAS Mutational Heterogeneity between Paired Primary and Metastatic Melanoma Tumors.
    Chang GA; Wiggins JM; Corless BC; Syeda MM; Tadepalli JS; Blake S; Fleming N; Darvishian F; Pavlick A; Berman R; Shapiro R; Shao Y; Karlin-Neumann G; Spittle C; Osman I; Polsky D
    J Invest Dermatol; 2020 Aug; 140(8):1609-1618.e7. PubMed ID: 32087194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRAF, NRAS and MC1R status in a prospective series of primary cutaneous melanoma.
    García-Casado Z; Traves V; Bañuls J; Niveiro M; Gimeno-Carpio E; Jimenez-Sanchez AI; Moragón M; Onrubia JA; Oliver V; Kumar R; Nagore E
    Br J Dermatol; 2015 Apr; 172(4):1128-31. PubMed ID: 25385688
    [No Abstract]   [Full Text] [Related]  

  • 16. The molecular profile of metastatic melanoma in Australia.
    Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
    Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinicopathological characteristics and mutation profile of BRAF and NRAS mutation in cutaneous melanomas in the Western Turkish population.
    Evrenos MK; Temiz P; Çam FS; Yaman M; Yoleri L; Ermertcan AT
    Turk J Med Sci; 2018 Oct; 48(5):973-979. PubMed ID: 30384563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.
    Pracht M; Mogha A; Lespagnol A; Fautrel A; Mouchet N; Le Gall F; Paumier V; Lefeuvre-Plesse C; Rioux-Leclerc N; Mosser J; Oger E; Adamski H; Galibert MD; Lesimple T
    J Eur Acad Dermatol Venereol; 2015 Aug; 29(8):1530-8. PubMed ID: 25623140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular characterization of a selected cohort of patients affected by pulmonary metastases of malignant melanoma: Hints from BRAF, NRAS and EGFR evaluation.
    Ulivieri A; Cardillo G; Manente L; Paone G; Mancuso AP; Vigna L; Di Stasio E; Gasbarra R; Girlando S; Leone A
    Oncotarget; 2015 Aug; 6(23):19868-79. PubMed ID: 26305188
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.